Diffuse Cutaneous Systemic Sclerosis Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Baseline (Day 1) Visit. Approximately 300 participants who meet the trial eligibility criteria will be randomized on Day 1 in a 1:1:1 ratio to receive HZN-825 300 mg QD, HZN-825 300 mg BID or placebo for 52 weeks. The trial will include up to a 42-day Screening Period and a 52-week Double-blind Treatment Period. Participants will take their first dose of trial drug at the clinic and will participate in trial visits at Week 4 and every 6 weeks thereafter until Week 52. All participants who complete the Double-blind Treatment Period (Week 52) will be eligible to enter a 52-week extension trial (HZNP-HZN-825-302, NCT05626751). Participants not entering the extension trial will participate in a Safety Follow-up Visit 4 weeks after the last dose of trial drug.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | July 2025 |
Est. primary completion date | July 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Written informed consent. 2. Male or female between the ages of 18 and 75 years, inclusive, at Screening. 3. Meets the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for SSc with a total score of =9 (Van den Hoogen et al., 2013). 4. Classified as having skin involvement proximal to the elbow and knee (diffuse cutaneous SSc subset by LeRoy and Medsger, 2001). 5. At the time of enrollment, less than or equal to 72 months (6 years) since the onset of the first SSc manifestation, other than Raynaud's phenomenon. 6. Skin thickening from SSc in the forearm suitable for repeat biopsy. 7. mRSS units =15 at Screening. 8. FVC =45% predicted at Screening, as determined by spirometry. 9. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial. Exclusion Criteria: 1. Positive for anti-centromere antibodies with the exception that subjects who are positive for both anti-centromere and anti-topoisomerase 1 antibodies may be enrolled. 2. Diagnosed with sine scleroderma or limited cutaneous SSc. 3. Diagnosed with other autoimmune connective tissue diseases, except for fibromyalgia, scleroderma-associated myopathy and secondary Sjogren's syndrome. 4. Scleroderma renal crisis diagnosed within 6 months of the Screening Visit. 5. Any of the following cardiovascular diseases: 1. uncontrolled, severe hypertension (=160/100 mmHg) or persistent low blood pressure (systolic blood pressure <90 mmHg) within 6 months of Screening, 2. myocardial infarction within 6 months of Screening, 3. unstable cardiac angina within 6 months of Screening. 6. DLCO <40% predicted (corrected for hemoglobin). If severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure is of clinical concern for any subject, consider using a DLCO up to 6 months before the Screening Visit. 7. Pulmonary arterial hypertension (PAH) by right heart catheterization requiring treatment with more than 1 oral PAH-approved therapy or any parenteral therapy. Treatment is allowed for erectile dysfunction and/or Raynaud's phenomenon/digital ulcers. 8. Corticosteroid use for conditions other than SSc within 4 weeks prior to Screening (topical steroids for dermatological conditions and inhaled/intranasal/intra-articular steroids are allowed). 9. Use of any other non-steroid immunosuppressive agent, small biologic molecule, cytotoxic or anti-fibrotic drug within 4 weeks of Screening, including cyclophosphamide, azathioprine (Imuran®) or other immunosuppressive or cytotoxic medication. Exceptions include mycophenolate mofetil (CellCept®), mycophenolic acid (Myfortic®), methotrexate and low-dose prednisone, as follows: use of CellCept =3 g/day, Myfortic =2.14 g/day, methotrexate =20 mg/week and prednisone =10 mg/day (or equivalent dosing of glucocorticoids) is allowed. Subjects taking CellCept, Myfortic or methotrexate must have been doing so for =6 months and the dose must have been stable for =4 weeks prior to the Day 1 Visit. Prednisone must have been at a stable dose for =8 weeks prior to the Day 1 Visit. It is acceptable to be on background low-dose prednisone and anti-malarial drug along with CellCept, Myfortic or methotrexate. Rituximab must not have been used within 6 months of the Day 1 Visit. 10. Known active bacterial, viral, fungal, mycobacterial or other infection, including tuberculosis or atypical mycobacterial disease (fungal infections of nail beds are allowed) at the time of randomization. 11. Use of a United States Food and Drug Administration-approved agent for SSc or an investigational agent for any condition within 90 days or 5 half-lives, whichever is longer, prior to Screening or anticipated use during the course of the trial. 12. Malignant condition in the past 5 years (except successfully treated basal/squamous cell carcinoma of the skin or cervical cancer in situ). 13. Women of childbearing potential or male subjects not agreeing to use highly effective method(s) of birth control throughout the trial and for 1 month after last dose of trial drug. Male subjects must refrain from sperm donation and females from egg/ova donation for this same time period. 14. Pregnant or lactating women. 15. Current drug or alcohol abuse or history of either within the previous 2 years, in the opinion of the Investigator or as reported by the subject. 16. Previous enrollment in this trial or participation in a prior HZN-825 or SAR100842 clinical trial. 17. Known history of positive test for human immunodeficiency virus (HIV). HIV testing is optional based on Investigator assessment, institutional practices or local guidelines to rule out suspected HIV or potential for a positive HIV result. Subject consent is required prior to HIV testing. 18. Active hepatitis (hepatitis B: positive hepatitis B surface antigen and positive anti-hepatitis B core antibody [anti-HBcAb] and negative hepatitis B surface antibody [HBsAb] or positive for HBcAb with a positive test for HBsAb and with presence of hepatitis B virus DNA at Screening; hepatitis C: positive anti-hepatitis C virus [anti-HCV] and positive RNA HCV). 19. Current alcoholic liver disease, primary biliary cirrhosis or primary sclerosing cholangitis. 20. Previous organ transplant (including allogeneic and autologous marrow transplant). 21. International normalized ratio >2, prolonged prothrombin time >1.5 × the upper limit of normal (ULN) or partial thromboplastin time >1.5 × ULN at Screening. 22. Alanine aminotransferase or aspartate aminotransferase >2 × ULN. 23. Estimated glomerular filtration rate <30 mL/min/1.73 m^2 at Screening. 24. Total bilirubin >2 × ULN. Subjects with documented diagnosis of Gilbert's syndrome may be enrolled if their total bilirubin is =3.0 mg/dL. 25. Any other condition that, in the opinion of the Investigator, would preclude enrollment in the trial. |
Country | Name | City | State |
---|---|---|---|
Argentina | Aprillus Asistencia e Investigacion de Arcis Salud SRL | Ciudad Autónoma de Buenos Aires | |
Argentina | Clínica Adventista Belgrano | Ciudad Autónoma de Buenos Aires | |
Argentina | Consultorio Médico Dra. Rivera | Ciudad Autónoma de Buenos Aires | |
Argentina | Organización Médica de Investigación | Ciudad Autónoma de Buenos Aires | |
Argentina | Framingham Centro Médico | La Plata | Buenos Aires |
Argentina | I.R. Medical Center - Hospital de Dia | Mendoza | |
Argentina | Consultorios Médicos Dr. Catalán Pellet | Recoleta | Ciudad Autónoma De BuenosAires |
Argentina | Centro de Investigaciones Médicas Tucumán | San Miguel de Tucuman | Tucumán |
Argentina | Clinica Mayo de U.M.C.B. S.R.L | San Miguel de Tucumán | Tucumán |
Argentina | Consultorio de Investigaciones Reumatologicas | San Miguel De Tucumán | Tucumán |
Austria | Medizinische Universität Graz | Graz | Steiermark |
Austria | Medizinische Universitat Wien (Medical University of Vienna) | Wien | |
Chile | Centro de Investigación Clínica de la Universidad Católica | Santiago | |
Chile | Oncocentro APYS | Viña del Mar | Valparaíso |
France | Centre Hospitalier Universitaire de Bordeaux, Hopital Pellegrin | Bordeaux | Gironde |
France | Hôpital Claude Huriez | Lille | Nord |
France | Hopital Cochin | Paris | |
France | Hôpitaux Universitaires de Strasbourg | Strasbourg | Bas-Rhin |
France | Hôpital de Rangueil | Toulouse | Haute-Garonne |
Germany | Charité - Universitätsmedizin Berlin | Berlin | |
Germany | Universitätsklinikum Carl Gustav Carus an der TU Dresden | Dresden | |
Germany | Universitatsklinikum Dusseldorf | Düsseldorf | Nordrhein-Westfalen |
Germany | Friedrich Alexander Universität Erlangen Nürnberg | Erlangen | Bayern |
Germany | Universitätsklinikum Freiburg | Freiburg | Baden-Württemberg |
Germany | Universität Georg August | Göttingen | Niedersachsen |
Germany | Universitatsklinikum Halle (Saale) | Halle | Sachsen-Anhalt |
Germany | LMU Klinikum der Universität | München | Bayern |
Germany | Universitätsklinikum Würzburg | Würzburg | Bayern |
Greece | Laiko General Hospital of Athens | Athens | Attiki |
Greece | Laiko General Hospital of Athens | Athina | Attiki |
Greece | Ippokratio General Hospital of Thessaloniki | Thessaloniki | |
Greece | Kianous Stavros | Thessaloniki | |
Israel | Lady Davis Carmel Medical Center | Haifa | |
Israel | Rambam Medical Center - PDDS | Haifa | |
Israel | Meir Medical Center | Kfar Sava | HaMerkaz |
Israel | Rabin Medical Center | Petah tikva | |
Israel | Tel Aviv Sourasky Medical Center | Tel Aviv-Yafo | Tel-Aviv |
Israel | Sheba Medical Center | Tel HaShomer | |
Italy | Azienda Ospedaliera Universitaria Careggi | Firenze | Toscana |
Italy | Ospedale Policlinico San Martino | Genova | Liguria |
Italy | Ospedale San Raffaele S.r.l. - PPDS | Milano | Lombardia |
Italy | Fondazione IRCCS Policlinico San Matteo di Pavia | Pavia | Lombardia |
Italy | Azienda Ospedaliero Universitaria Pisana | Pisa | |
Italy | Fondazione Policlinico Universitario A Gemelli | Roma | Lazio |
Italy | Istituto Clinico Humanitas | Rozzano | Lombardia |
Italy | Azienda Sanitaria Universitaria Friuli Centrale - PO Universitario Santa Maria della Misericordia | Udine | Friuli-Venezia Giulia |
Japan | Juntendo University Hospital | Bunkyo-Ku | Tokyo |
Japan | Kyushu University Hospital | Fukuoka | |
Japan | Saitama Medical University Hospital | Iruma-Gun | Saitama |
Japan | Kitasato University Medical Center | Kitamoto-Shi | Saitama |
Japan | Kumamoto University Hospital | Kumamoto-Shi | Kumamoto |
Japan | Nagasaki University Hospital | Nagasaki-Shi | Nagasaki |
Japan | Hokkaido University Hospital | Sapporo-Shi | Hokkaidô |
Japan | Sapporo Medical University Hospital | Sapporo-Shi | Hokkaidô |
Japan | Tohoku University Hospital | Sendai-shi | Miyagi |
Japan | Tokyo Women's Medical University Hospital | Shinjuku-ku | Tokyo |
Japan | Osaka University Hospital | Suita-Shi | Ôsaka |
Japan | Osaka Medical and Pharmaceutical University Hospital | Takatsuki-Shi | Ôsaka |
Japan | Nippon Medical School Hospital | Tokyo | |
Japan | St. Luke's International Hospital | Tokyo | |
Japan | Fujita Health University Hospital | Toyoake-shi | Aiti |
Korea, Republic of | Chonnam National University Hospital | Gwangju | |
Korea, Republic of | Hanyang University Seoul Hospital | Seongdong-gu | Seoul Teugbyeolsi |
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam | Gyeonggido |
Korea, Republic of | Gangnam Severance Hospital, Yonsei University Health System | Seoul | |
Mexico | Centro de Alta Especialidad En Reumatologia E Investigacion Del Potosi SC | Burócratas del Estado | San Luis Potosí |
Mexico | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Ciudad de México | Distrito Federal |
Mexico | Centro de Estudios de Investigacion Basica Y Clinica SC | Guadalajara | Jalisco |
Mexico | Centro Integral Reumatologia SA de CV | Guadalajara | Jalisco |
Mexico | Clinica de Investigacion en Reumatologia y Obesidad | Guadalajara | |
Mexico | Unidad de Atencion Medica e Investigacion en Salud | Merida | Yucatán |
Mexico | CITER, Centro de Investigacion y Tratamiento de las Enfermedades Reumaticas SA de CV | Mexico | Distrito Federal |
Mexico | Centro de Investigación y Tratamiento Reumatológico S.C | Miguel Hidalgo | Distrito Federal |
Netherlands | Universitair Medisch Centrum Groningen | Groningen | |
Netherlands | Leids Universitair Medisch Centrum | Leiden | Zuid-Holland |
Poland | Malopolskie Centrum Kliniczne | Kraków | Malopolskie |
Poland | MCM Krakow - PRATIA | Kraków | |
Poland | FutureMeds - Lodz - PPDS | Lódz | |
Poland | Twoja Przychodnia NCM | Nowa Sól | Lubuskie |
Poland | Ortopedyczno-Rehabilitacyjny Szpital Kliniczny im. Wiktora Degi | Poznan | Wielkopolskie |
Poland | Centrum Medyczne Reuma Park NZOZ | Warszawa | Mazowieckie |
Poland | Medicover Integrated Clinical Services sp. z o.o | Warszawa | Mazowieckie |
Portugal | Hospital Garcia de Orta | Almada | Setúbal |
Portugal | Hospital de Braga | Braga | |
Portugal | Centro Hospitalar E Universitário de Coimbra EPE | Coimbra | |
Portugal | Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria | Lisboa | |
Portugal | Hospital Conde de Bertiandos Unidade Local de Saúde Do Alto Minho | Ponte De Lima | |
Portugal | Centro Hospitalar de São João, E.P.E. | Porto | |
Romania | Centrul Medical de Diagnostic si Tratament Ambulator NEOMED SRL | Brasov | |
Romania | Sf.Maria Clinical Hospital | Bucharest | Bucuresti |
Romania | Sf.Maria Clinical Hospital | Bucharest | Bucuresti |
Romania | Dr I Cantacuzino Clinical Hospital | Bucuresti | |
Spain | Hospital Universitario A Coruña | a Coruña | |
Spain | Hospital de La Santa Creu i Sant Pau | Barcelona | |
Spain | Hospital Universitario Vall d'Hebron | Barcelona | |
Spain | C.H. Regional Reina Sofia | Cordoba | Córdoba |
Spain | Hospital General Universitario Gregorio Marañon | Madrid | |
Spain | Hospital Universitario La Paz - PPDS | Madrid | |
Spain | Hospital de Merida-Avenida d' Antonio Campos Hoyos 26 | Merida | Badajoz |
Spain | Corporacio Sanitaria Parc Tauli | Sabadell | Barcelona |
Spain | Hospital Universitario Marques de Valdecilla | Santander | Cantabria |
Spain | Hospital Quironsalud Infanta Luisa | Sevilla | |
Spain | Hospital Universitario Virgen del Rocio | Sevilla | |
Spain | Hospital Universitario Doctor Peset | Valencia | |
Switzerland | Inselspital Bern | Bern | Bern (de) |
Switzerland | HFR Fribourg Hôpital Cantonal | Fribourg | |
Switzerland | Kantonsspital St. Gallen | Sankt Gallen | |
United Kingdom | The Royal Free Hospital | London | London, City Of |
United States | Michigan Medicine University of Michigan | Ann Arbor | Michigan |
United States | Boston University School Of Medicine | Boston | Massachusetts |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | Metroplex Clinical Research Center | Dallas | Texas |
United States | Duke University Medical Center | Durham | North Carolina |
United States | UT Physicians Rheumatology | Houston | Texas |
United States | Pacific Arthritis Care Center | Los Angeles | California |
United States | UCLA Department of Medicine | Los Angeles | California |
United States | University of Miami Miller School of Medicine | Miami | Florida |
United States | DelRicht Clinical Research, LLC | New Orleans | Louisiana |
United States | Hospital For Special Surgery | New York | New York |
United States | Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania |
United States | Arizona Arthritis and Rheumatology Research, PLLC | Phoenix | Arizona |
United States | IRIS Research and Development LLC | Plantation | Florida |
United States | Mayo Clinic - Cancer Center - Rochester - PPDS | Rochester | Minnesota |
United States | Stanford University School of Medicine | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Horizon Therapeutics Ireland DAC |
United States, Argentina, Austria, Chile, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Romania, Spain, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in FVC (forced vital capacity) percent predicted from Baseline to Week 52 | As measured by a pulmonary function test called a spirometry. | Baseline to Week 52 | |
Secondary | Change from Baseline in HAQ-DI (Health Assessment Questionnaire - Disability Index) at Week 52 | Baseline to Week 52 | ||
Secondary | Change from Baseline in MDGA (Physician Global Assessment) at Week 52 | Baseline to Week 52 | ||
Secondary | Change from Baseline in PTGA (Patient Global Assessment) at Week 52 | Baseline to Week 52 | ||
Secondary | Change from Baseline in the Physical Effects subscale of the scleroderma skin patient-reported outcome (SSPRO-18) at Week 52 | Baseline to Week 52 | ||
Secondary | Change from Baseline in the Physical Limitations subscale of the scleroderma skin patient-reported outcome SSPRO-18 at Week 52 | Baseline to Week 52 | ||
Secondary | Proportion of participants with an mRSS (modified Rodnan skin score) decrease of =5 points and 25% from Baseline at Week 52 | Baseline to Week 52 | ||
Secondary | Responder rate (defined as ACR-CRISS [predicted probability] of at least 0.6) at Week 52 | American College of Rheumatology-Composite Response Index in Systemic Sclerosis | Week 52 | |
Secondary | Proportion of participants with an improvement in =3 of 5 core measures from Baseline: =20% in mRSS, =20% in HAQ-DI, =20% in PTGA, =20% in MDGA and =5% for FVC % predicted at Week 52 (ACR-CRISS-20) | American College of Rheumatology-Composite Response Index in Systemic Sclerosis | Baseline to Week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02161406 -
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Completed |
NCT03222492 -
Brentuximab Vedotin for Systemic Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT04137224 -
Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)
|
Phase 2 | |
Not yet recruiting |
NCT04986605 -
Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Completed |
NCT02503644 -
Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Enrolling by invitation |
NCT05626751 -
An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)
|
Phase 2 | |
Withdrawn |
NCT05098145 -
A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis
|
Phase 1/Phase 2 | |
Terminated |
NCT04478994 -
A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1 | |
Completed |
NCT03198689 -
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Terminated |
NCT04680975 -
Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Completed |
NCT00433186 -
Mycophenolate Mofetil in Systemic Sclerosis
|
Phase 1 | |
Terminated |
NCT03919799 -
KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Not yet recruiting |
NCT06152172 -
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
|
Phase 1 | |
Suspended |
NCT04166552 -
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Not yet recruiting |
NCT06375005 -
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
|
Phase 2 | |
Recruiting |
NCT05270668 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
|
Phase 2 | |
Recruiting |
NCT05168215 -
Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.
|
||
Completed |
NCT04440592 -
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
Recruiting |
NCT05149768 -
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
|
Phase 2 | |
Withdrawn |
NCT04138485 -
Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)
|
Phase 2 |